Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b/2a immuno-oncology trial of HyLeukin-7 in combination with atezolizumab in patients with anti-PD-(L)1 naïve or refractory high-risk skin cancers.

Trial Profile

Phase 1b/2a immuno-oncology trial of HyLeukin-7 in combination with atezolizumab in patients with anti-PD-(L)1 naïve or refractory high-risk skin cancers.

Planning
Phase of Trial: Phase I/II

Latest Information Update: 04 May 2018

At a glance

  • Drugs Atezolizumab (Primary) ; GX I7 (Primary)
  • Indications Skin cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors NeoImmuneTech
  • Most Recent Events

    • 04 May 2018 New trial record
    • 01 May 2018 According to the NeoImmuneTech media release, this trial will be led by NIT and the Immune Oncology Network.
    • 01 May 2018 According to the NeoImmuneTech media release, this trial is anticipated to start in the second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top